<unk>  is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
Infigratinib
Selpercatinib
Tucatinib
Fostamatinib
Neratinib
Brigatinib
Capmatinib
Lapatinib